January 25, 2023 11:18 AM EST

FDA adcomm votes in favor of new antifungal; Denali gets $25M from Sanofi MS trial milestone

Lei Lei Wu

News Reporter

Tyler Patchen

News Reporter

The FDA’s Antimicrobial Drugs Advisory Committee voted 14-1 in favor of a limited-use indication for Cidara Therapeutics’ rezafungin, a treatment for candidemia and invasive candidiasis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA adcomm votes in favor of new antifungal; Denali gets $25M from Sanofi MS trial milestone

Lei Lei Wu

News Reporter

Tyler Patchen

News Reporter

Sign up to read this article for free.

New fund will pressure flailing biotechs, as investor frustration boils over

Akeso shares new data suggesting it can beat Keytruda on survival, wins China approval

Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient

AbbVie commits $10B to expand US footprint with the threat of tariffs ahead

FDA chief Makary talks expediting drug approvals, RIFs and the abortion pill

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

FDA ad­comm votes in fa­vor of new an­ti­fun­gal; De­nali gets $25M from Sanofi MS tri­al mile­stone

News Reporter

News Reporter

Sign up to read this article for free.

FDA adcomm votes in favor of new antifungal; Denali gets $25M from Sanofi MS trial milestone